PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.

In the Phase Ib study KEYNOTE-524, the combination of lenvatinib and pembrolizumab achieved an ORR of unresectable HCC of 36.0% ( 114 ), but its Phase III trial LEAP-002 did not reach the primary end point of the study, but showed a trend toward beneficial activity.

also in 53,322 other papers